Genetic testing, powered for prostate cancer

Improve outcomes with genetic testing


Why consider genetic testing for prostate cancer?

According to a recent NEJM study:

  • >11%  of men with metastatic prostate cancer have an inherited mutation
  • Patients with metastatic prostate cancer are 4X more likely to have a BRCA1 and BRCA2 mutation
  • 40.3%  of men with BRCA2 mutations are more likely to develop advanced prostate cancer
  • Family history alone cannot reliably predict an inherited DNA-repair defect that may have risk of disease associated with metastatic prostate cancer

Invitae Prostate Cancer Panel

This test analyzes up to 14 genes associated with a hereditary predisposition to prostate cancer.

  • Primary panel: ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PMS2, TP53
  • Add-on preliminary evidence genes: PALB2, RAD51D

The most frequent pathogenic variants detected in men with prostate cancer are in BRCA1, BRCA2, MSH2, and HOXB13.  

  • HOXB13 increases lifetime risk up to 60%
  • BRCA1 and BRCA2 increase lifetime risk by about 20%

Who should be considered for genetic testing?

Individuals with a personal or family history of:

  • prostate cancer with a Gleason score  ≥7
  • prostate, breast, ovarian, uterine, colon, pancreatic, melanoma, or sarcoma, particularly if early onset (<50)
  • male breast cancer
  • Ashkenazi Jewish ancestry and breast or ovarian cancer

Simple pricing. Simple billing. No surprises.

  • Panel testing that lets you take cost out of the equation, with no explanation of benefits >$1500 ever
  • Clinical Consult Services to help identify the right test for each patient and clarify results, at no additional charge

Fast, customizable testing

Quick turnaround

Results available in 10–21 calendar days (14 days on average).

Clinical support

Expert advice and counseling for you and your patient when you need it.

Learn more

Need more answers?

Order additional genes within the original clinical area at no additional charge within 90 days.

Learn more